Julius Clinical are proud to announce the successful completion of recruitment for the PRImus-AD study, a clinical Phase II study which investigates the safety and efficacy of the drug candidate PRI-002 for the treatment of Alzheimer's Disease....
At Julius Clinical, we are proud to announce the first formal meeting of our Dementia Scientific Advisory Board (SAB) with Prof. Philip Scheltens and Prof. John Harrison—a major milestone in our commitment to advancing dementia research and clin...
"*" indicates required fields
"*" indicates required fields
Julius Clinical and Peachtree BioResearch Solutions Merge to Form a Fully Integrated Global CRO with Increased CNS Capabilities. Read more here
